Gold prices slide further as easing US-China tensions curb haven demand
Romeo R. Dizon, Chief Financial Officer of Iridex Corp (NASDAQ:IRIX), recently purchased 1,000 shares of the company’s common stock at $1.35 per share, in a transaction totaling $1,350. The stock has since risen to $1.41, with the medical technology company currently valued at approximately $24 million. According to InvestingPro analysis, the company maintains a FAIR financial health score despite facing profitability challenges.
The transaction, which occurred on September 5, 2025, was disclosed in a Form 4 filing with the Securities and Exchange Commission. Following the purchase, Dizon directly owns 55,750 shares of Iridex. InvestingPro analysis reveals 6 additional key insights about IRIX’s financial position and market performance, available in the comprehensive Pro Research Report, which provides deep-dive analysis of over 1,400 US stocks.
In other recent news, IRIDEX Corporation reported its second-quarter earnings for 2025, delivering results that surpassed analysts’ expectations. The company achieved an earnings per share (EPS) of -$0.06, beating the projected -$0.09. Additionally, IRIDEX reported revenue of $13.6 million, exceeding the anticipated $13.1 million. These figures highlight a stronger-than-expected financial performance for the quarter. The earnings announcement was followed by notable market activity, although specific stock price movements are not detailed here. These recent developments reflect positively on IRIDEX’s financial outlook. Analyst firms have not been mentioned regarding any upgrades or downgrades, focusing solely on the company’s earnings and revenue achievements.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.